close
1.

論文(リポジトリ)

論文(リポジトリ)
小方, 則夫
出版情報: 新潟医学会雑誌 = 新潟医学会雑誌.  110  pp.556-565,  1996-12.  新潟医学会
本文リンク: http://hdl.handle.net/10191/43554
概要: After eradication of posttransfusion hepatiis B and C, we are confronted with sporadic occurrence of viral hepatitis. Ep idemiological studies indicate that hepatitis B is likely to be a sexually transmitted disease(STD), but hepatitis C is not. Incidence of the establishment of the infection largely depends on the virus amount of the index cases. Therefore, examination of virus amount of carries is likely to be the most important predictor of the infection. At present a goal of control of hepatitis B and C is to prevent the occurrence of fulminant hepatitis B and chronic hepatitis C, because the both are occasionally fatal. Our molecular studies suggest that the genetic mutation of the core promoter region of HBV would be one virus factor for the development of fulminant hepatitis B and that the presence of the hypervariable region of HCV might be one virus factor for the establishment of chronic hepatitis C. However, these findings have not yet directly utilized in the clinical fields. Hepatitis GB virus, originally known as the GB hepatitis agent, is recently molecularly cloned. The GB virus seems to belong to Family Flaviviridae and actually exists in humans including patients with non-ABCDE hepatitis. Since etiology of 20% of patients with possible virus hepatitis is unknown, hepatitis GB virus would partly account for the cause of these diseases. An essential strategy for prevention of virus infection is undoubtedly the primordial prevention. For the prevention of STD by hepatitis viruses social education is needed as in the case of AIDS. 続きを見る
2.

論文(リポジトリ)

論文(リポジトリ)
小俣, 政男
出版情報: 新潟医学会雑誌 = 新潟医学会雑誌.  112  pp.661-666,  1998-11.  新潟医学会
本文リンク: http://hdl.handle.net/10191/46331
概要: Recent increase of hepatocellular carcinoma (HCC) is so noticeable, in that hepatitis C virus (HCV) infection contributes to the majority (83%) of the neoplasm. Prospective follow-up study indicates C-viral HCC develops stepwise depending upon the degree or stage of liver fibrosis. Thus, we can predict the chance of developing the neoplasm by liver biopsy staging in C-viral chronic liver disease. Recent introduction of Interferon revealed HCV could be eradicated in 30% of those treated, and reduction in the HCC occurrence among them was demonstrated. These results clearly indicate that, by combining meticulous interventional and medical treatment for HCC and anti-viral therapy for the virus, future development of HCC could be drastically reduced in our country. 続きを見る
3.

論文(リポジトリ)

論文(リポジトリ)
小島, 秀男 ; 大竹, 幸子 ; 富樫, 和枝 ; 石口, 重子 ; 山田, 恵子 ; 品田, 章二
出版情報: 新潟医学会雑誌 = 新潟医学会雑誌.  104  pp.992-998,  1990-12.  新潟医学会
本文リンク: http://hdl.handle.net/10191/35151
概要: Post transfusion Hepatitis (PTH) is one of serious side effects and some times lead to fulminant hepatic failure in case transfused blood contain very low level (under the sensitivity of usual screening method) of hepatitis B virus (HBV). Redcross blood center and blood transfusion devision of our hospital have been employed reverse passive hemmaglutination method (RPHA) for HBsAg screening. Authors employed EIA for sensitive HBsAg test system and compared with RPHA method. Of 2,255 sera from blood bonors, 21 sera showed HBsAg by EIA. Of those 21 HBsAg sera, 4 were negative for HBsAg when tested by RPHA. So about 20% of HBsAg positive sera containing very low level HBV and RPHA could not detect them. For the prevention of post transfusion type B hepatitis, authors changed the HBsAg screening method to EIA. Relationship with so called non-A non-B hepatitis and anti-HCV was investigted. Anti-HCV was detected frequently in patients clinically diagnosed as non-A non-B hepatitis, and correlation of anti-HCV positivity and blood transfusion indicates the importance of the anti-HCV screening in blood transfusion. 続きを見る
4.

論文(リポジトリ)

論文(リポジトリ)
大桃, 幸夫
出版情報: 新潟医学会雑誌 = 新潟医学会雑誌.  103  pp.644-651,  1989-08.  新潟医学会
本文リンク: http://hdl.handle.net/10191/41373
概要: Efficacy and rationale of our scheduled protocol were studied, as to a measure for prevention of vertical HBvirus transmission to the babies. We examined on 70 babies whose mother were positive for HBsAg and HBeAg. The protocol was administration of HB-immunoglobulin (HBIG) within 48 hours after birth when the umbilical cord serum was negative for HBsAg, followed by vaccination with inactivated HB-virus for three times at 2 months, 3 months and 5 months after birth. The results obtained are as follows; 1. Three cases out of 70 became HB-carriers by 2 months after birth, although HBIG was administerd to the cases. Out of remaining 67 cases treated as scheduled, one became HB-carrier at 1 year old and another one case became transiently positive for HBsAg at 7 months after birth. Sixty-five cases out of the 70 babies (92.9%) were thus successfully prevented from being HB-carrier. 2. In these 65 cases, times of the vaccination necessary for acquiring active immunity were analyzed. Fifty-four cases out of 65 infants (85.1%) gained sufficient anti-HBsAb titer (titer of 2^2) by 2 to 3 times of vaccination, and 9 cases (13.8%) by 4 times of vaccination. Two cases (4.6%), however, rembined to be negative for HBsAb even after 4 times of vaccination. 3. The titer of serum anti-HBsAb was serially examined by passive hemagglutinin (PHA) method in 46 cases who have been followed up for more than 12 months after birth. In more than 50% of the cases who had produced sufficient anti-HBs at 6th or 8th month, significantly high titer of anti-HBs was found to persist 24th month after the birth. 4. The mean value of anti-HBs antibody titer at 6th or 8th month after birth was 2^<3.6> and the half life of anti HBs-titer in the babies was estimated to be 12.65 month. These data strongly suggested that the protocol adopted in this study was an effective and rational one for preventing the vertical transmission of HB-virus from mothers positive for HBeAg to the babies. It was also confirmed that the amount of anti-HBs antibody produced under this protocol regimen persisted at least as long as the 24th month after birth. 続きを見る